 |
|
Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Interventions—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Sharma and colleagues point out that we excluded patients with acute myocardial infarction from our trial, as has been the policy for virtually all broad-based trials of PCI. Ongoing myocardial infarction at the time of enrollment influences both the administration of other antithrombotic agents prior to randomization and the ascertainment of clinical end points, essentially precluding diagnosis of periprocedural myocardial necrosis. For these and other reasons, patients with acute infarction are usually studied in trials specifically dedicated to percutaneous revascularization in that setting. As we noted in our article, "patients with acute myocardial infarction or unstable ischemic syndromes requiring empiric Gp IIb/IIIa inhibition were not included in the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial, and the results of this trial should not be interpreted to suggest that Gp IIb/IIIa blockade should be supplanted in those patients." Future studies are planned, however, . . . [Full Text of this Article]
A. Michael Lincoff, MD;
Eric J. Topol, MD
Cleveland Clinic Foundation
Cleveland, Ohio
for the REPLACE-2 Investigators
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Interventions
Sanjiv Sharma, William Nyitray, and Brijesh Bhambi
JAMA. 2003;290(11):1451.
EXTRACT
| FULL TEXT
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann III, Edward T. A. Fry, Augustin DeLago, Charles Wilmer, Eric J. Topol, and for the CREDO Investigators
JAMA. 2002;288(19):2411-2420.
ABSTRACT
| FULL TEXT
|
